Articles
Latest Articles
Commentaries
Deals
Distillery
Emerging Companies
Finance
Politics, Policy & Law
Product Development
Regulation
Targets & Mechanisms
Tools & Techniques
Current Editions
Search Archives
BCIQ
Company Profiles
Target Profiles
Product Profiles
Conferences
China Healthcare Summit
Bio€quity Europe
White Papers
Free Trial
/
Subscribe
Sign In
more_vert
Biocentury
Company Profiles
Target Profiles
Product Profiles
Free Trial Information
Export Pdf
Overview
Pipeline
Deals
Financings
Earnings Summary
Stock Summary
Articles
BioCentury
|
Mar 16, 1998
Finance
Glaxo thinks ROI
...a contributing associate. Managing partner Sam Isaly founded OrbiMed in January after the breakup of
Mehta & Isaly
...
Read More
BioCentury
|
Jan 12, 1998
Finance
Tale of two markets
...declined to comment. WHAT ISALY IS UP TO: Samuel Isaly, a co-founder of recently dissolved
Mehta & Isaly
...
Read More
BioCentury
|
Sep 29, 1997
Finance
Ebb & Flow Focus: Summer paradox
...rotation and biotech is now the hot sector," said Sven Borho, assistant portfolio manager for
Mehta & Isaly
...
Read More
BioCentury
|
Jul 7, 1997
Finance
What doth summer bring?
...said Sven Borho, an associate portfolio manager at G\A Capital Management, the buyside arm of
Mehta & Isaly
...
Read More
BioCentury
|
Mar 24, 1997
Emerging Company Profile
Ontogeny Inc.
...raised: $41 million Investors: Greylock; Sutter Hill; Whitney; One Liberty; Charles River; Medical Science Partners;
Mehta & Isaly
...
Read More
BioCentury
|
Aug 12, 1996
Finance
Party of one
...said Sven Borho, an associate portfolio manager at G\A Capital Management, the buyside arm of
Mehta & Isaly
...
Read More
BioCentury
|
Jun 24, 1996
Finance
The 'C' word
...ITRC . . . Paul Boni left
Mehta & Isaly
...
...ITRC . . . Paul Boni left
Mehta & Isaly
...
Read More
BioCentury
|
Mar 18, 1996
Finance
Efficient markets?
...and prevent organ transplant rejection. Collaborative (Cleveland, Ohio) is a clinical research organization. LAST WORD:
Mehta & Isaly
...
Read More
BioCentury
|
Nov 6, 1995
Strategy
The low-ball bid for Immunex
...pivotal trials in infectious disease. IMNX's medium-term opportunity is its TNF receptor. Edmund Debler of
Mehta & Isaly
...
Read More
BioCentury
|
Jan 23, 1995
Analyst Picks & Changes
Analyst picks & changes
...if its recently announced public offering for 1 million shares is completed. Edmund Debler of
Mehta & Isaly
...
Read More
Items per page:
10
1 - 10 of 17
BioCentury
|
Mar 16, 1998
Finance
Glaxo thinks ROI
...a contributing associate. Managing partner Sam Isaly founded OrbiMed in January after the breakup of
Mehta & Isaly
...
Read More
BioCentury
|
Jan 12, 1998
Finance
Tale of two markets
...declined to comment. WHAT ISALY IS UP TO: Samuel Isaly, a co-founder of recently dissolved
Mehta & Isaly
...
Read More
BioCentury
|
Sep 29, 1997
Finance
Ebb & Flow Focus: Summer paradox
...rotation and biotech is now the hot sector," said Sven Borho, assistant portfolio manager for
Mehta & Isaly
...
Read More
BioCentury
|
Jul 7, 1997
Finance
What doth summer bring?
...said Sven Borho, an associate portfolio manager at G\A Capital Management, the buyside arm of
Mehta & Isaly
...
Read More
BioCentury
|
Mar 24, 1997
Emerging Company Profile
Ontogeny Inc.
...raised: $41 million Investors: Greylock; Sutter Hill; Whitney; One Liberty; Charles River; Medical Science Partners;
Mehta & Isaly
...
Read More
BioCentury
|
Aug 12, 1996
Finance
Party of one
...said Sven Borho, an associate portfolio manager at G\A Capital Management, the buyside arm of
Mehta & Isaly
...
Read More
BioCentury
|
Jun 24, 1996
Finance
The 'C' word
...ITRC . . . Paul Boni left
Mehta & Isaly
...
...ITRC . . . Paul Boni left
Mehta & Isaly
...
Read More
BioCentury
|
Mar 18, 1996
Finance
Efficient markets?
...and prevent organ transplant rejection. Collaborative (Cleveland, Ohio) is a clinical research organization. LAST WORD:
Mehta & Isaly
...
Read More
BioCentury
|
Nov 6, 1995
Strategy
The low-ball bid for Immunex
...pivotal trials in infectious disease. IMNX's medium-term opportunity is its TNF receptor. Edmund Debler of
Mehta & Isaly
...
Read More
BioCentury
|
Jan 23, 1995
Analyst Picks & Changes
Analyst picks & changes
...if its recently announced public offering for 1 million shares is completed. Edmund Debler of
Mehta & Isaly
...
Read More
Items per page:
10
1 - 10 of 17
Previous page
Next page